CN Patent

CN113286587A — 用于治疗iv型胶原病的联苯磺酰胺化合物

Assigned to Traville Treatment Co · Expires 2021-08-20 · 5y expired

What this patent protects

本发明提供了治疗Alport综合征和与IV型胶原缺乏相关的其他疾病，以及防止与其相关的听力丧失的方法，包括施用具有结构(I)的化合物或其药学上可接受的盐， 或者施用包含结构(I)所示的化合物或其药学上可接受的盐的药物组合物。

USPTO Abstract

本发明提供了治疗Alport综合征和与IV型胶原缺乏相关的其他疾病，以及防止与其相关的听力丧失的方法，包括施用具有结构(I)的化合物或其药学上可接受的盐， 或者施用包含结构(I)所示的化合物或其药学上可接受的盐的药物组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN113286587A
Jurisdiction
CN
Classification
—
Expires
2021-08-20
Drug substance claim
No
Drug product claim
No
Assignee
Traville Treatment Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.